Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS

Next Previous
X
Search
Trial Profile

PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MOMA

    • Most Recent Events

    • 15 Jun 2020 A pooled analysis of five prospective trials; results published in the European Journal of Cancer
    • 05 Feb 2019 Results published in the European Journal of Cancer
    • 24 May 2018 Results of an analysis validating loss of chromosome 18q11.2-q12.1, as the predictive factor for survival in patients with metastatic colorectal cancer treated with Bevacizumab using data from three additional multicenter cohorts (Angiopredict cohort, MOMA cohort and NoBev cohort), published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top